A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...
It has been recommended as an additional treatment for patients with epidermal growth factor receptor (EGFR) ...
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.
Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...
Cancer still eludes treatment, and tumors frequently evolve resistance mechanisms to get around medications. By making cancer ...
A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...
Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...